WHAT IS CLAIMED IS:

1. Use of (*R*)-N-(2,2-difluoroethyl)-7-methyl-l,2,3,4,6,7-hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8- carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a 5-hydroxytryptamine $(HT)_{2C}$ receptor-associated disorder in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

2. Use of (*R*)-N-(2,2-difluoroethyl)-7-methyl-l,2,3,4,6,7- hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of epilepsy in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

3. Use of (*R*)-N-(2,2-difluoroethyl)-7-methyl- l,2,3,4,6,7-hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing severity of an epileptic seizure in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

4. Use of (*R*)-N-(2,2-difluoroethyl)-7-methyl- l,2,3,4,6,7-hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the frequency of epileptic seizures in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

5. Use of (*R*)-N-(2,2-difluoroethyl)-7-methyl- l,2,3,4,6,7-hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, the

manufacture of a medicament for the treatment or prevention of a seizure disorder in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

6. The use of claim 5, wherein the seizure disorder is selected from epilepsy, epilepsy with generalized tonic-clonic seizures, epilepsy with myoclonic absences, frontal lobe epilepsy, temporal lobe epilepsy, Landau-Kleffher Syndrome, Rasmussen's syndrome, Dravet syndrome, Doose syndrome (epilepsy with myoclonic atonic seizures (EM AS)), CDKL5 deficiency disorder (CDKL5 encephalopathy, or CDD), infantile spasms (West syndrome), juvenile myoclonic epilepsy (JME), vaccine-related encephalopathy, intractable childhood epilepsy (ICE), Lennox-Gastaut syndrome (LGS), Rett syndrome, Ohtahara syndrome (early infantile DEE, EIDEE), childhood absence epilepsy, essential tremor, acute repetitive seizures, benign rolandic epilepsy, status epilepticus, refractory status epilepticus, super-refractory status epilepticus (SRSE), PCDH19 pediatric epilepsy, drug withdrawal induced seizures, alcohol withdrawal induced seizures, increased seizure activity and breakthrough seizures.

7. Use of (*R*)-N-(2,2- difluoroethyl)-7-methyl-l,2,3,4,6,7-hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of developmental and epileptic encephalopathy (DEE) in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

8. The use of claim 7, wherein the DEE is selected from Ohtahara syndrome (EIDEE), Lennox-Gastaut syndrome, Dravet syndrome, Doose syndrome (EM AS), West syndrome (infantile spasms), Landau-Kleffner syndrome, tuberous sclerosis complex, CDKL5 encephalopathy (CDKL5 deficiency disorder), dup15q syndrome, SCN2A related epilepsies, SCN8A related epilepsies, KCNQ2 related epilepsies, KCNQ3 related epilepsies, Angelman syndrome, KCNT1 related epilepsies, SynGAP1 related epilepsies, Rett syndrome, PCDH19 epilepsy, ring 14 syndrome, ring 20 syndrome, CHD2 encephalopathy, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, and epileptic encephalopathy

with continuous spike-wave.

9. Use of (*R*)-N-(2,2-difluoroethyl)-7-methyl- l,2,3,4,6,7-hexahydro-[l,4]diazepino[6,7,l-*hi*]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention a refractory epilepsy in a patient in need thereof,

wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered twice daily.

10. The use of any of claims 1–9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered in a dosage equivalent to about 3 mg/dose of Compound 1.

11. The use of any of claims 1–9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered in a dosage equivalent to about 6 mg/dose of Compound 1.

12. The use of any of claims 1–9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered in a dosage equivalent to about 12 mg/dose of Compound 1.

13. The use of any of claims 1–9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered in a dosage equivalent to about 15 mg/dose of Compound 1.

14. The use of any of claims 1–9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered in a dosage equivalent to about 18 mg/dose of Compound 1.

15. The use of any of claims 1–9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is to be administered via a titration scheme that comprises the up- titration of Compound 1, or a pharmaceutically acceptable salt thereof, until an optimized dosage is administered.

16. The use of claim 14 or claim 15, wherein the titration scheme further comprises the down-titration of Compound 1, or a pharmaceutically acceptable salt thereof.

17. The use of any of claims 1–16, wherein the patient has Dravet syndrome.

18. The use of any of claims 1–16, wherein the patient has Lennox-Gastaut Syndrome.

19. The use of any of claims 1–18, wherein the Compound 1, or a pharmaceutically acceptable salt thereof, is an HCl salt of Compound 1.

20. The use of any of claims 1–19, wherein the administration results in a ratio of a geometric mean steady-state C_{trough} of Compound 1 in CSF to a geometric mean steady-state C_{trough} of Compound 1 in plasma (CSF/P C_{trough}) of at least about 1.4.